Treatment of Inoperable Stage III or Stage IV Thymoma
This protocol addresses the management of thymoma that has reached advanced local or distant spread and cannot be surgically removed at presentation.
Clinical scenario: Patients with inoperable stage III or stage IV thymoma require a systemic treatment strategy, as complete surgical resection is not feasible at the time of diagnosis or evaluation.
Treatment approach
The primary treatment involves chemotherapy, which may be followed by radiation therapy. In selected cases where resection becomes feasible after initial treatment, surgery combined with radiation may be considered.
Multiple chemotherapy regimens are available for this scenario. The complete protocol — including regimen selection, sequencing, and evidence summaries — is available via the link below.
References
- Treatment options for patients with inoperable stage III and stage IV thymoma include:
- An intergroup trial conducted in the United States reported a predicted 5-year OS rate of 52% in 26 patients who received the PAC chemotherapy regimen (cisplatin, doxorubicin, cyclophosphamide) followed by radiation therapy without surgery.
- The ADOC regimen (doxorubicin, cisplatin, vincristine, cyclophosphamide) was given to 37 patients.
- A study of combined chemotherapy with cisplatin and etoposide reported:
- Patients with invasive thymoma or thymic carcinoma were treated with four cycles of etoposide, ifosfamide, and cisplatin (VIP) at 3-week intervals.
- A phase II study evaluated the activity of a combination of carboplatin and paclitaxel in 46 patients with unresectable TETs, including 21 patients with unresectable thymoma.
View source ↗